References
- ResnikoffSPascoliniDEtya’aleDGlobal data on visual impairment in the year 2002Bull World Health Organ2004821184485115640920
- SharifNAWilliamsGWKellyCRBimatoprost and its free acid are prostaglandin FP receptor agonistsEur J Pharmacol20014322–321121311740958
- PatilAJVajaranantTSEdwardDPBimatoprost – a reviewExpert Opin Pharmacother200910162759276819874254
- Lumigan® [Package insert]Irvine, CAAllergan, Inc2006
- KatzLJCohenJSBatoosinghALFelixCShuVSchiffmanRMTwelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertensionAm J Ophthalmol20101494661671e120346780
- MajumdarSHippalgaonkarKRepkaMAEffect of chitosan, benzalkonium chloride and ethylenediaminetetraacetic acid on permeation of acyclovir across isolated rabbit corneaInt J Pharm20083481–217517817897799
- KellerNMooreDCarperDLongwellAIncreased corneal permeability induced by the dual effects of transient tear film acidification and exposure to benzalkonium chlorideExp Eye Res19803022032107418740
- HowACKumarRSChenYMA randomised crossover study comparing bimatoprost and latanoprost in subjects with primary angle closure glaucomaBr J Ophthalmol200993678278619336424
- WilliamsRDCohenJSGrossRLLiuCCSafyanEBatoosinghALfor Bimatoprost Study GroupLong-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: Year 4Br J Ophthalmol200892101387139218621791
- CantorLBHoopJMorganLWudunnDCatoiraYfor Bimatoprost-Travoprost Study GroupIntraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertensionBr J Ophthalmol200690111370137316825272
- NakamuraTYamadaMTeshimaMElectrophysiological characterization of tight junctional pathway of rabbit cornea treated with ophthalmic ingredientsBiol Pharm Bull200730122360236418057726
- McCareyBEdelhauserHIn vivo corneal epithelial permeability following treatment with prostaglandin analogs with or without benzalkonium chlorideJ Ocul Pharmacol Ther200723544545117941807
- EpsteinSPAhdootMMarcusEAsbellPAComparative toxicity of preservatives on immortalized corneal and conjunctival epithelial cellsJ Ocul Pharmacol Ther200925211311919284328
- EpsteinSPChenDAsbellPAEvaluation of biomarkers of inflammation in response to benzalkonium chloride on corneal and conjunctival epithelial cellsJ Ocul Pharmacol Ther200925541542419857103
- NoeckerRJHerrygersLAAnwaruddinRCorneal and conjunctival changes caused by commonly used glaucoma medicationsCornea200423549049615220734
- LazarusHMImperiaPSBottiREMackRJLassJHAn in vitro method which assesses corneal epithelial toxicity due to antineoplastic, preservative and antimicrobial agentsLens Eye Toxic Res198961–259852488034
- HorsleyMBKahookMYEffects of prostaglandin analog therapy on the ocular surface of glaucoma patientsClin Ophthalmol2009329129519668581
- UusitaloHChenEPfeifferNSwitching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medicationActa Ophthalmol201088332933620546237